Quipt shareholders to receive US$3.65 per share in cashTransaction provides immediate liquidity and certainty of value to shareholdersThe per share purchase price represents a 162% premium to Quipt’s unaffected stock price on May 19, 2025, the last full trading day prior to the public disclosure of Forager’s $3.10 per share proposal, and a 54% premium to Quipt’s 30-day VWAP as of December 12, 2025 CINCINNATI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT ...

Core Insights - McFarlane Lake Mining Limited has received an Exploration Permit for the Juby Gold Project, marking a significant milestone for the company as it prepares for a major drilling campaign [1][2][3] Exploration Permit and Drilling Plans - The Exploration Permit allows for various activities including diamond drilling, line cutting, and geophysical surveys, enabling the company to execute an expanded drilling program targeting priority areas identified through geological modeling [3][5] - The company has established partnerships with two drilling contractors, including Bagone'an and Wiijiiwaagan Drilling Limited Partnership, which involve local First Nations, enhancing operational depth and community participation [4][5] 2026 Drill Program Objectives - The upcoming 2026 drill program is anticipated to be one of the most significant in the project's history, aiming to expand known mineralized zones, evaluate new targets, and strengthen relationships with local and Indigenous communities [6][7] Mineral Resource Estimates - The current Mineral Resource Estimate (as of September 29, 2025) indicates 1.01 million ounces of gold in the Indicated category at an average grade of 0.98 g/t gold, and an additional 3.17 million ounces in the Inferred category at an average grade of 0.89 g/t gold [8][9] - A sensitivity analysis at a higher gold price of US$3,750 per ounce suggests an increase in the Indicated Mineral Resource to 1.20 million ounces and Inferred Mineral Resource to 4.23 million ounces [9] Company Overview - McFarlane Lake Mining Limited is focused on advancing its flagship Juby Gold Project located in the Abitibi Greenstone Belt, with a portfolio of 100%-owned gold assets across Ontario [12]

Vancouver, BC, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Trident Resources Corp. (TSX-V: ROCK) (OTCQB: TRDTF) (“Trident” or the “Company”) is pleased to announce the appointment of Paul Kremer as Exploration Manager working alongside the existing geological team led by VP Exploration, Cornell McDowell. The Board of Directors and Management enthusiastically welcome Mr. Kremer to the team as Trident accelerates its exploration programs across Saskatchewan’s highly prospective gold belts. Mr. Kremer joins Trident foll ...

HONG KONG, Dec. 15, 2025 (GLOBE NEWSWIRE) -- 3 E Network Technology Group Limited (Nasdaq: MASK) (the “Company” or “3 E Network”), a business-to-business (“B2B”) information technology (“IT”) business solutions provider with the inspiration to become a next-generation artificial intelligence (“AI”) infrastructure solutions provider, today announced the execution of a Master Services Agreement (the “Agreement”) with Orka Technologies Oy ("Orka Technologies"), a Finnish company, to jointly develop an AI data ...

TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Aecon Group Inc. (TSX: ARE) (“Aecon”) announced today that the Board of Directors approved its next quarterly dividend of 19 cents per share. The dividend will be paid on January 5, 2026 to shareholders of record as of December 24, 2025. About Aecon Aecon Group Inc. (TSX: ARE) is a North American construction and infrastructure development company with global experience. Aecon delivers integrated solutions to private and public-sector clients through its Constructi ...

THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) WITH THE FOOD AND DRUG ADMINISTRATION (FDA) IN H1 2026 PHILADELPHIA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that its Phase 2 clinical study ...

Core Insights - Dyadic Applied BioSolutions has entered into a commercial agreement with Opes Diagnostics Limited to support the launch of its recombinant proteins for serum-free cell culture media applications in various markets [1][2][4] Company Overview - Dyadic is a global biotechnology company that produces precision-engineered, animal-free proteins and enzymes for life science, food & nutrition, and bioindustrial markets [1][5] - The company utilizes proprietary microbial expression platforms to manufacture recombinant proteins, which are designed to enable customers to develop more efficient and sustainable products [5] Partnership Details - Under the agreement, Opes will leverage its existing relationships to identify potential customers primarily in Europe, Israel, and Asia, facilitating market entry for Dyadic's recombinant protein portfolio [2][3] - The collaboration aims to enhance the penetration of Dyadic's products in industries such as research, diagnostics, cultured meat, and biomanufacturing [3][4] Market Strategy - The partnership is expected to drive the adoption of Dyadic's cell culture media products into expanding markets, transitioning the company from development activities to broader commercial engagement [4]

Financial Calendar - A.P. Møller - Mærsk A/S plans to publish its Annual Report for 2025 on 5 February 2026 [3] - The Interim Report for the 1st quarter is scheduled for 7 May 2026 [3] - The Interim Report for the 2nd quarter is set for 6 August 2026 [3] - The Interim Report for the 3rd quarter will be released on 5 November 2026 [3] Annual General Meeting - The Annual General Meeting is expected to be held on Wednesday, 25 March 2026 [2] - Any issues for the agenda must be received by the Company no later than 10 February 2026 [2]

Core Insights - Orelabrutinib is the first BTK inhibitor to show significant clinical activity in a Phase 2 clinical trial for Systemic Lupus Erythematosus (SLE) [1] - Zenas BioPharma has acquired exclusive rights to develop, manufacture, and commercialize orelabrutinib for Multiple Sclerosis (MS) globally, and for non-oncology fields outside Greater China and Southeast Asia [1][5] Clinical Trial Results - In the Phase 2b study, 187 patients were randomized into three groups: orelabrutinib 75 mg once-daily, orelabrutinib 50 mg once-daily, and placebo [2] - The primary endpoint, SLE Response Index-4 (SRI-4) response rate at week 48, was met with the 75 mg group showing a response rate of 57.1% compared to 34.4% for placebo (p < 0.05) [2] - Secondary endpoints, including SRI-6 and British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response rates, were also significantly higher in the 75 mg group compared to placebo (p < 0.05) [3] Safety and Tolerability - Orelabrutinib was well tolerated, exhibiting a safety profile consistent with BTK inhibition and the disease biology of SLE [3] Development Pipeline - Zenas is advancing orelabrutinib into a Phase 3 trial for Primary Progressive MS (PPMS) and plans to initiate a Phase 3 trial for Secondary Progressive MS (SPMS) in Q1 2026 [6] - Orelabrutinib is already approved for B cell malignancies in mainland China and Singapore, marketed by InnoCare [6] Company Overview - Zenas BioPharma is a clinical-stage global biopharmaceutical company focused on developing transformative therapies for autoimmune diseases [7] - The company is advancing two late-stage molecules: obexelimab and orelabrutinib, with obexelimab being a bifunctional monoclonal antibody targeting CD19 and FcγRIIb [7][8]

Core Insights - Kraig Biocraft Laboratories, Inc. has successfully completed its latest production cycle, yielding over one million BAM-1 Alpha hybrid eggs, which will be released in the upcoming quarter for recombinant spider silk production [1][2]. Production and Technology Advancements - The BAM-1 Alpha line has shown greater uniformity and resiliency throughout the production process, leading to improved throughput, consistency, and reliability for the company's spider silk manufacturing platform [2][3]. - The production capacity increase from BAM-1 Alpha is driving the company's expansion initiatives in Southeast Asia [3]. Strategic Outlook - The company has developed an aggressive production schedule for the next six months based on the successful results from BAM-1 Alpha and is already implementing this plan [4]. - The reliability and robustness of the BAM-1 Alpha line are enabling the company to confidently advance its commercial rollout [4].